Market Overview - The S&P 500 index reached a high of 5,670 in July but has shown volatility with a downward trend recently due to geopolitical tensions and sluggish GDP growth [1] - The U.S. Federal Reserve is expected to implement expansionary policies before the end of 2024, potentially leading to multiple rate cuts next year, which will support GDP growth [2] Li Auto (LI) - Li Auto's stock has corrected by 48% year-to-date, driven by negative sentiment in the EV industry and bearish views on Chinese stocks, but is considered undervalued with a forward P/E of 16.7 [4] - The company reported a cash buffer of $13.7 billion as of Q1 2024, allowing for investment in innovation and expansion [5] - Li Auto achieved a vehicle margin of 19.3% and reported a 25.5% year-on-year growth in vehicle deliveries for Q2 2024, indicating potential for a rally from oversold levels [6] Miniso Group (MNSO) - Miniso's stock has declined by 22% year-to-date, but is viewed as a buy with a forward P/E of 12.7 and a dividend yield of 2.6% [8] - The company reported a revenue growth of 26% for Q1 2024, reaching $515.7 million, with an adjusted EBITDA margin increase of 200 basis points to 25.9% [9] - Miniso plans to open 900 to 1,100 new stores annually from 2024 to 2028, expecting revenue growth at a CAGR of over 20% during this period [10] Marathon Digital (MARA) - Marathon Digital's stock is considered undervalued with a strong growth outlook, reporting a 78% year-on-year revenue growth to $145.1 million for Q2 2024 [12] - The company has an energized hash rate of 31.5 EH/s, which increased by 78% year-on-year, and expects to reach a capacity of 50 EH/s by year-end [13] - Marathon reported a liquidity buffer of $1.4 billion as of Q2 2024, providing flexibility for aggressive investments [13] IAMGOLD (IAG) - IAMGOLD's stock has surged by 110% in the last 12 months, with a forward P/E of 11, indicating attractive valuations [16] - The company is expected to benefit from higher gold prices, with gold trading at $2,460 an ounce and potential to reach $3,000 in the next 6 to 18 months [15] - IAMGOLD commenced production at the Côté Gold assets, with expectations for revenue and cash flow growth [16] Tempus AI (TEM) - Tempus AI is a new player in healthcare technology, reporting a 25% year-on-year revenue growth to $166 million for Q2 2024, with data licensing revenue increasing by 40% [19] - The company has expanded its immune-oncology portfolio and received approval for its next-generation sequencing analysis, positioning it for future growth [20] PACS Group (PACS) - PACS Group reported a 31% year-on-year revenue growth to $1.9 billion for the first half of 2024, with increased revenue and adjusted EBITDA guidance [22] - The company added 167 skilled nursing beds in Q2, and its mature facilities have an occupancy rate of 94.2%, supporting robust revenue growth [23] Cronos (CRON) - Cronos reported a 46% year-on-year revenue growth to $27.8 million for Q2 2024, supported by new market expansions [25] - The company has a cash buffer of $848 million, providing flexibility for growth initiatives [24] - Cronos is expected to achieve EBITDA break-even by 2025, indicating potential for significant stock appreciation [26]

With the current market volatility, knowing which biotech stocks to buy on the dip can lead to lucrative returns as the industry is likely to recover faster than the market average. After all, many of the most prominent biomedical developers see their stock price rise or fall based on their drug success.That’s because no matter the market conditions, the critical medicines produced by biotech companies remain in demand by the patient populations that rely on them. For example, the price of insulin, no matte ...

Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day. The Nasdaq 100 lost more than 1,000 points at one point, its worst loss ever, before regaining some of the lost ground.Although the situation turned markedly better by Tuesday and continued improving as the week progressed, the whipsaw event still has investors cautious. Wild swing trades can often signal a new, worse crash is coming. That’s why it’s important to prepare for ...

On the morning of August 5, the unwinding of the Yen carry trade accelerated, leading to a spike in the expected volatility index. Investors were selling and asking questions later. Even the best e-commerce stocks suffered under this carnage. That pullback has created an opportunity to buy into one of the most enduring themes of our time.The thesis for e-commerce stocks is straightforward. There has been a gradual shift from physical shopping to online shopping. After all, who doesn’t love shopping from the ...

Core Viewpoint - The global industrial automation market is expected to grow at a CAGR of 8.3% from 2024 to 2031, but the robotics sector may face challenges due to economic slowdown and reduced capital expenditures, leading to potential vulnerabilities in certain robotics stocks [1]. Group 1: Dynatrace (DT) - Dynatrace operates in the software performance niche, focusing on application performance management (APM) and cloud-native monitoring, which are critical for automation processes [3][4]. - The company holds a 3% market share in the APM market and faces stiff competition from major players like Microsoft, Amazon, Google, IBM, and Cisco, making it a candidate for selling [5]. - Despite a 19% year-over-year revenue increase in Q2 2024, net income showed minimal growth at 1.1%, indicating potential stagnation [6]. Group 2: PROCEPT Biorobotics (PRCT) - PROCEPT Biorobotics is known for its AquaBeam Robotic System, which uses waterjet technology for treating benign prostate enlargement (BPH), a condition affecting up to 90% of men over 80 [7][8]. - In Q2 2024, the company reported 47 sales of the AquaBeam system, generating $53.4 million in revenue, reflecting a 61% annual growth, but it has not yet achieved profitability [9]. - The company reported a net loss of $25.6 million, slightly higher than the previous year's loss, indicating ongoing financial challenges [10]. Group 3: Zebra Technologies (ZBRA) - Zebra Technologies connects employees with assets across various sectors, including logistics and healthcare, and made a significant acquisition of Fetch Robotics for $290 million to enhance its warehouse automation capabilities [11][12]. - Competitor Symbotic may offer better exposure in the market, as it utilizes AI-powered software for optimizing robotic operations and has established partnerships with major retail chains [13][14]. - ZBRA stock has increased nearly 20% year-to-date, priced at $320, while Symbotic's stock has decreased significantly, presenting a potential high-growth opportunity [15].

The past decade and a half have truly been incredible for investors. Most could have chosen from a list of top-performing growth stocks and done just fine for themselves. Many of the largest and what many consider the “best” growth stocks have outperformed smaller counterparts, which isn’t usually the case.In recent months, the stock market environment has been much more turbulent than in the past. Volatility has picked up as various macro forces continue to shift, and global dynamics remain in flux.However ...

Meta Platforms (NASDAQ:META) stock saw a 14% increase last week, outpacing the 4% return for the S&P 500. This strong performance was driven by a positive market response to Meta’s earnings report, highlighting second-quarter results in its core advertising business.The stock’s recent rally marks a significant turnaround from the previous quarter, when concerns over Meta’s AI investments led to a sharp decline in its share price. The high stock price growth reflects growing street optimism about Meta’s capa ...

Microsoft’s (NASDAQ:MSFT) fiscal fourth-quarter results, unveiled on July 30, showed that the tech giant’s Azure cloud unit continues to expand very quickly. Moreover, the firm is benefiting meaningfully from the AI boom. It should also get a significant lift from the refresh of its operating system that’s currently under way. Finally the firm is well-positioned to benefit from potential acquisitions in the AI and cybersecurity spaces over the longer term. With the valuation of Microsoft stock reasonably at ...

Core Viewpoint - The market has shown signs of calm after recent volatility, but investors remain cautious and are likely to react negatively to bad news, making defensive stocks appealing [1][2]. Defensive Stocks Overview Campbell Soup (CPB) - Campbell Soup is a leading manufacturer of packaged foods, benefiting from increased grocery shopping during economic challenges. The company reported an average EPS of $0.74, exceeding the consensus of $0.71, and offers a dividend yield of 3.06% with a payout ratio of just under 60% [3][4]. Consolidated Edison (ED) - Consolidated Edison operates as a utility provider in New York, benefiting from its natural monopoly status. The company reported an average EPS of $1.34, beating the consensus of $1.25, and offers a forward dividend yield of 3.26% with a payout ratio of 63.69% [6][7]. Medtronic (MDT) - Medtronic specializes in medical devices and therapies for chronic diseases, reporting an average EPS of $1.30, surpassing the consensus of $1.25. The company offers a forward dividend yield of 3.45%, but has a high payout ratio of 100% [8][9]. Colgate-Palmolive (CL) - Colgate-Palmolive produces oral and personal care products, with an average EPS of $0.88, exceeding the consensus of $0.83. The company has a dividend yield around 2% and a payout ratio under 57% [10][11]. Walmart (WMT) - Walmart is a major player in retail, providing essential goods at low prices. The company has a forward dividend yield of 1.21% and a low payout ratio of 33.37%. Analysts project sales of $676.5 billion for the current fiscal year, a 13.7% increase from last year [12][13]. Philip Morris (PM) - Philip Morris, a tobacco company, reported an average EPS of $1.53, slightly above the expected $1.51. The company offers a forward yield of 4.48% with a payout ratio of 92% [14][15]. Gilead Sciences (GILD) - Gilead Sciences focuses on antiviral drugs, reporting an average EPS of $1.15, beating the consensus of $0.92. The company offers a dividend yield of 4.22% with a high payout ratio, and analysts expect revenue of $27.64 billion for fiscal 2024, a 9.1% increase from last year [16][17].

The United States may be about to witness antitrust history. Recently, a federal judge handed down a warning against Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), ruling that Google holds an unfair monopoly over the search engine market. Described as the “biggest tech antitrust case in decades,” this ruling may already be about to yield action. According to reports, the U.S. Department of Justice is considering taking steps to break up the Google monopoly. Indeed, after years of politicians floating the possibility ...